In neuroblastomas, miR-17-92 cluster shows oncogenic activity and attenuates the TGF-β signaling pathway by repressing the expression of SMAD2, SMAD4 and TGF-β receptor 2 52. Here, SMAD2 is linked to neuroblastoma.